Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Metrics to compare | CDIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCDIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −1.9x | −0.5x | |
PEG Ratio | −0.02 | −0.11 | 0.00 | |
Price/Book | 0.7x | 0.9x | 2.6x | |
Price / LTM Sales | 390.5x | 19.4x | 3.2x | |
Upside (Analyst Target) | - | 159.4% | 42.7% | |
Fair Value Upside | Unlock | 28.9% | 5.8% | Unlock |